The collaboration between HKSTP and Boehringer Ingelheim Venture Fund (BIVF) aims to nurture novel startups with groundbreaking technologies for infectious diseases and immunology. With BIVF's focus on developing unprecedented therapeutic concepts paired with their extensive biotech funding network, early-stage startups and promising university spinoffs can access vital funding opportunities, investment insights, and mentorship guidance. This co-incubation programme will fast-track high quality startups worldwide to develop breakthrough therapies and assist in the clinical translation for significant enhancements in patient care.